These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36266939)

  • 1. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
    Liwinski T; Hübener S; Henze L; Hübener P; Heinemann M; Tetzlaff M; Hiller MI; Jagemann B; Surabattula R; Leeming D; Karsdal M; Monguzzi E; Schachschal G; Rösch T; Bang C; Franke A; Lohse AW; Schuppan D; Schramm C
    Aliment Pharmacol Ther; 2023 Jan; 57(2):224-236. PubMed ID: 36266939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective function of sclerosing cholangitis on IBD.
    Bedke T; Stumme F; Tomczak M; Steglich B; Jia R; Bohmann S; Wittek A; Kempski J; Göke E; Böttcher M; Reher D; Franke A; Lennartz M; Clauditz T; Sauter G; Fründt T; Weidemann S; Tiegs G; Schramm C; Gagliani N; Pelczar P; Huber S
    Gut; 2024 Jul; 73(8):1292-1301. PubMed ID: 38839272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A; Fish J; Carman N; Walters TD; Church PC; Hansen BE; Crowley E; Siddiqui I; Nguyen GC; Kamath BM; Griffiths AM
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1098-1105.e1. PubMed ID: 29378308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis.
    Stumme F; Steffens N; Steglich B; Mathies F; Nawrocki M; Sabihi M; Soukou-Wargalla S; Göke E; Kempski J; Fründt T; Weidemann S; Schramm C; Gagliani N; Huber S; Bedke T
    Front Immunol; 2024; 15():1307297. PubMed ID: 38510236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
    Bjarnason I; Hayee B; Pavlidis P; Kvasnovsky C; Scalori A; Sisson G; Charlesworth A; Shaikh H; Bjornsson E; Heneghan MA
    EBioMedicine; 2015 Oct; 2(10):1523-7. PubMed ID: 26629548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis.
    Kim YS; Hurley EH; Park Y; Ko S
    Exp Mol Med; 2023 Jul; 55(7):1380-1387. PubMed ID: 37464092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis.
    Wittek A; Steglich B; Casar C; Seiz O; Huber P; Ehlken H; Reher D; Wende S; Bedke T; Kempski J; Böttcher M; Bang C; Thingholm L; Krech T; Lohse AW; Sauter G; Rösch T; Franke A; Schramm C; Gagliani N; Pelczar P; Huber S
    Inflamm Bowel Dis; 2024 Jun; 30(6):900-910. PubMed ID: 37540889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis.
    Shah A; Jones MP; Callaghan G; Fairlie T; Ma X; Culver EL; Stuart K; De Cruz P; O'Beirne J; Tabibian JH; Dignass A; Canbay A; Gores GJ; Holtmann GJ
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38206197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis.
    Gui W; Hole MJ; Molinaro A; Edlund K; Jørgensen KK; Su H; Begher-Tibbe B; Gaßler N; Schneider CV; Muthukumarasamy U; Mohs A; Liao L; Jaeger J; Mertens CJ; Bergheim I; Strowig T; Hengstler JG; Hov JR; Marschall HU; Trautwein C; Schneider KM
    Nat Commun; 2023 Jun; 14(1):3304. PubMed ID: 37280200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease.
    Azzam N; AlRuthia Y; Alharbi O; Aljebreen A; Almadi M; Loftus EV
    Hepatol Int; 2020 Dec; 14(6):1114-1124. PubMed ID: 33369708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis.
    Schaeffer DF; Win LL; Hafezi-Bakhtiari S; Cino M; Hirschfield GM; El-Zimaity H
    Dig Dis Sci; 2013 Sep; 58(9):2608-14. PubMed ID: 23670229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.
    Ostadmohammadi S; Azimirad M; Houri H; Naseri K; Javanmard E; Mirjalali H; Yadegar A; Sadeghi A; Asadzadeh Aghdaei H; Zali MR
    Mol Biol Rep; 2021 Jul; 48(7):5519-5529. PubMed ID: 34304365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
    Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
    Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Christensen B; Micic D; Gibson PR; Yarur A; Bellaguarda E; Corsello P; Gaetano JN; Kinnucan J; Rao VL; Reddy S; Singh S; Pekow J; Rubin DT
    Aliment Pharmacol Ther; 2018 Mar; 47(6):753-762. PubMed ID: 29377235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients.
    Jørgensen KK; Grzyb K; Lundin KE; Clausen OP; Aamodt G; Schrumpf E; Vatn MH; Boberg KM
    Inflamm Bowel Dis; 2012 Mar; 18(3):536-45. PubMed ID: 21456044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease.
    Torres J; Palmela C; Brito H; Bao X; Ruiqi H; Moura-Santos P; Pereira da Silva J; Oliveira A; Vieira C; Perez K; Itzkowitz SH; Colombel JF; Humbert L; Rainteau D; Cravo M; Rodrigues CM; Hu J
    United European Gastroenterol J; 2018 Feb; 6(1):112-122. PubMed ID: 29435321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.
    Bajer L; Kverka M; Kostovcik M; Macinga P; Dvorak J; Stehlikova Z; Brezina J; Wohl P; Spicak J; Drastich P
    World J Gastroenterol; 2017 Jul; 23(25):4548-4558. PubMed ID: 28740343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.